若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

RoboSep™- S

全自动细胞分选仪器

产品号 #(选择产品)

产品号 #21000_C

全自动细胞分选仪器

产品组分包括

RoboSep™-S 基础单元(产品号 #21001) “The Big Easy”EasySep™磁极(产品号 #18001) RoboSep™ 服务机架(产品号 #20101) RoboSep™ 试管套件(产品号 #20155) u盘 RoboSep™ 用户参考手册(产品号 #29792) RoboSep™ 快速入门指南(产品号 #28943) 1年保修(产品号 #21200)
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

总览

使用RoboSep™-S全自动细胞分选仪器。凭借EasySep™技术,RoboSep™-S能够完成所有必要的步骤,在进行磁珠标记后,通过阳选或阴选方式可分选出几乎任何细胞。RoboSep™-S旨在最大限度地减少样品处理量,消除交叉污染并缩短操作时间。

本仪器操作和维护所需的补充产品可单独购买,包括RoboSep™尖端抛光剂RoboSep™管套组件.

有关我们的自动细胞分选仪器的更多信息,请参阅我们的RoboSep™概述,并探索细胞分选试剂盒和配件用于RoboSep™。

提供租赁和保修服务。如需进一步信息,请与我们联系。

如需了解有关仪器服务的更多信息,包括额外的服务包和软件,请参阅我们的仪器概述页面.

包含
• RoboSep™-S Base Unit (Catalog #21001) • "The Big Easy" EasySep™ Magnets (Catalog #18001) • RoboSep™ Service Rack (Catalog #20101) • RoboSep™ Tube Kits (Catalog #20155) • USB Flash Drive • RoboSep™ User Reference Manual (Catalog #29792) • RoboSep™ Quick Start Guide (Catalog #28943) • 1-Year Warranty (Catalog #21200)
 
应用
细胞分选
 
品牌
RoboSep
 
研究领域
嵌合体,HLA,免疫,干细胞生物学
 

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
RoboSep™-S
Catalog #
21000
Lot #
All
Language
English
Document Type
Technical Manual
Product Name
RoboSep™-S
Catalog #
21000
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (30)

文献 (65)

Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study. H. W. Grievink et al. Frontiers in immunology 2022

Abstract

Currently immunomodulatory compounds are under investigation for use in patients with cardiovascular disease, caused by atherosclerosis. These trials, using recurrent cardiovascular events as endpoint, require enrollment of large patient groups. We investigated the effect of key risk factors for atherosclerosis development, ageing and smoking, on the immune system, with the objective to identify biomarkers differentiating between human populations, and potentially serving as endpoints for future phase 1B trials with immunomodulatory compounds. Blood was collected from young healthy volunteers (aged 18-25 years, n=30), young smokers (18-25 years, n=20), elderly healthy volunteers (>60 years, n=20), heavy smokers (>45 years, 15 packyears, n=11) and patients with stable coronary artery disease (CAD) (>60 years, n=27). Circulating immune cell subsets were characterized by flow cytometry, and collected plasma was evaluated by proteomics (Olink). Clear ageing effects were observed, mostly illustrated by a lower level in CD8+ and na{\{i}}ve CD4+ and CD8+ T cells with an increase in CD4+ and CD8+ effector memory T cells in elderly healthy volunteers compared to young healthy volunteers. Heavy smokers showed a more inflammatory cellular phenotype especially a shift in Th1/Th2 ratio: higher Th1 and lower Th2 percentages compared to young healthy volunteers. A significant decrease in circulating atheroprotective oxLDL-specific IgM was found in patients with CAD compared to young healthy volunteers. Elevated pro-inflammatory and chemotactic proteins TREM1 and CCL11 were observed in elderly volunteers compared to young volunteers. In addition heavy smokers had an increase in pro-inflammatory cytokine IL-6 and lysosomal protein LAMP3. These data show that ageing and smoking are associated with an inflammatory immunophenotype and that heavy smokers or aged individuals may serve as potential populations for future clinical trials investigating immunomodulatory drugs targeted for cardiovascular disease."
Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. J. Bae et al. Leukemia 2019 mar

Abstract

To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138+ tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a key myeloma-associated antigen. The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8+ CTL that mediate effective and long-lasting immunity against MM. Here we report the identification of novel engineered peptides specific to BCMA, BCMA72-80 (YLMFLLRKI), and BCMA54-62 (YILWTCLGL), which display improved affinity/stability to HLA-A2 compared to their native peptides and induce highly functional BCMA-specific CTL with increased activation (CD38, CD69) and co-stimulatory (CD40L, OX40, GITR) molecule expression. Importantly, the heteroclitic BCMA72-80 specific CTL demonstrated poly-functional Th1-specific immune activities [IFN-gamma/IL-2/TNF-alpha production, proliferation, cytotoxicity] against MM, which were correlated with expansion of Tetramer+ and memory CD8+ CTL. Additionally, heteroclitic BCMA72-80 specific CTL treated with anti-OX40 (immune agonist) or anti-LAG-3 (checkpoint inhibitor) display increased immune function, mainly by central memory CTL. These results provide the framework for clinical application of heteroclitic BCMA72-80 peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors.
Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection. M. Angin et al. Nature metabolism 2019 jul

Abstract

Spontaneous control of human immunodeficiency virus (HIV) is generally associated with an enhanced capacity of CD8+ T cells to eliminate infected CD4+ T cells, but the molecular characteristics of these highly functional CD8+ T cells are largely unknown. In the present study, using single-cell analysis, it was shown that HIV-specific, central memory CD8+ T cells from spontaneous HIV controllers (HICs) and antiretrovirally treated non-controllers have opposing transcriptomic profiles. Genes linked to effector functions and survival are upregulated in cells from HICs. In contrast, genes associated with activation, exhaustion and glycolysis are upregulated in cells from non-controllers. It was shown that HIV-specific CD8+ T cells from non-controllers are largely glucose dependent, whereas those from HICs have more diverse metabolic resources that enhance both their survival potential and their capacity to develop anti-HIV effector functions. The functional efficiency of the HIV-specific CD8+ T cell response in HICs is thus engraved in their memory population and related to their metabolic programme. Metabolic reprogramming in vitro through interleukin-15 treatment abrogated the glucose dependency and enhanced the antiviral potency of HIV-specific CD8+ T cells from non-controllers.

更多信息

更多信息
Contains • RoboSep™-S Base Unit (Catalog #21001) • "The Big Easy" EasySep™ Magnets (Catalog #18001) • RoboSep™ Service Rack (Catalog #20101) • RoboSep™ Tube Kits (Catalog #20155) • USB Flash Drive • RoboSep™ User Reference Manual (Catalog #29792) • RoboSep™ Quick
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.